Concepedia

Jeroen Lammerts van Bueren

JL

Statistics

Publications

6

Citations

357

H-Index

6

Active since

2012

Affiliations

Genmab (Netherlands)(Current)

Hospital Clínic de Barcelona

Consorci Institut D'Investigacions Biomediques August Pi I Sunyer

Institució Catalana de Recerca i Estudis Avançats

Josep Carreras Leukaemia Research Institute

Jeroen Lammerts van Bueren is an author at Genmab (Netherlands) specializing in immunotherapy, cancer immunotherapy, and monoclonal antibody therapy.

Publications per year

2012–2023

6

Publications

6

Direct in Vitro Comparison of Daratumumab with Surrogate Analogs of CD38 Antibodies MOR03087, SAR650984 and Ab79

Jeroen Lammerts van Bueren, Danielle Jakobs, Niels Kaldenhoven et al. · Blood · 2014 · 221 citations

, , +16

The Human CD38 Monoclonal Antibody Daratumumab Shows Antitumor Activity and Hampers Leukemia–Microenvironment Interactions in Chronic Lymphocytic Leukemia

Alba Matas‐Céspedes, Anna Vidal‐Crespo, Vanina Rodríguez et al. · Clinical Cancer Research · 2016 · 51 citations · Full text

, , +17

Daratumumab displays in vitro and in vivo anti-tumor activity in models of B-cell non-Hodgkin lymphoma and improves responses to standard chemo-immunotherapy regimens

Anna Vidal‐Crespo, Alba Matas‐Céspedes, Vanina Rodríguez et al. · Haematologica · 2019 · 43 citations · Full text

, , +17

Phagocytosis Is A Mechanism of Action for Daratumumab

Marije B. Overdijk, Sandra Verploegen, Bögels Marijn et al. · Blood · 2012 · 18 citations

, , +10

Daratumumab, a Novel Human Anti-CD38 Monoclonal Antibody for the Treatment of Chronic Lymphocytic Leukemia and B-Cell Non–Hodgkin Lymphoma

Alba Matas‐Céspedes, Anna Vidal‐Crespo, Vanina Rodríguez et al. · Blood · 2012 · 13 citations

, , +16

1–5 of 6